Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2011. The report discloses a specific corporate transaction regarding a notifiable share interest in Theravance, Inc., rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing does not provide data on GSK's overall revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to a specific investment transaction:
- Investment Amount: $6,689,254.40
- Shares Purchased: 261,299 shares of Theravance, Inc. Common Stock
- Price Per Share: $25.60
Material Changes
On May 3, 2011, GSK purchased additional shares of Theravance, Inc. to maintain its ownership percentage following the preceding quarter's net option exercise and equity vesting activity. Following this transaction, GSK's total interest in Theravance comprises 6,163,577 shares of Common Stock and 9,401,499 shares of Class A Common Stock.
Outlook and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the share purchase. The transaction is noted as disclosable under SEC rules.
Investor Verification Points
- Verify GSK's total ownership percentage in Theravance, Inc., which stands at approximately 19.01% post-transaction.
- Confirm the total outstanding capital stock of Theravance, Inc. used for the calculation (81,878,356 shares).
- Note that this filing does not contain GSK's quarterly or annual financial performance data.